AI-Powered OncologyDecision Support
Evidence-based treatment recommendations from 368 clinical scenarios across 23 tumor types, powered by advanced hybrid RAG retrieval.
Oncology Treatment Decisions Are Complex
Keeping up with rapidly evolving guidelines across dozens of tumor types is a daily challenge.
Guidelines Are Complex
Hundreds of pages across multiple tumor types with frequent updates
Time-Consuming to Search
Finding the right protocol for a specific clinical scenario takes valuable time
Risk of Missing Updates
New approvals and guideline changes can impact treatment decisions
OncoIA: Your Clinical Decision Partner
AI-powered retrieval of the most relevant NCCN guideline scenarios for your patient, with evidence-based recommendations in seconds.
How It Works
From clinical question to evidence-based recommendation in three steps
Describe Your Case
Enter patient details including tumor type, stage, biomarkers, and treatment history. Use natural language or structured input.
AI Analysis
Hybrid RAG retrieves the 25 most relevant clinical scenarios using dense embeddings + BM25, fused with Reciprocal Rank Fusion.
Get Recommendations
Receive treatment recommendations with confidence levels, supporting evidence, trial references, dosing, and toxicity management.
Comprehensive Clinical Intelligence
Everything you need for evidence-based oncology decision support
NCCN Guidelines 2025-2026
Latest treatment algorithms and clinical pathways from the National Comprehensive Cancer Network.
23+ Tumor Types
Comprehensive coverage from common (lung, breast, colorectal) to rare tumors (mesothelioma, neuroendocrine).
Drug Dosing & Toxicity
Detailed dosing regimens, dose modifications, and grade-based toxicity management protocols.
Biomarker-Driven
EGFR, HER2, BRCA, ALK, ROS1, MSI, TMB, NTRK, RET, BRAF, PD-L1 and more for precision oncology.
Drug Interactions
CYP450 interactions, QTc risks, renal/hepatic dose adjustments, and special population guidelines.
Export to PDF
Download consultation reports as professional PDFs with recommendations, evidence, and guideline references.
See OncoIA in Action
Ask a clinical question and get an evidence-based recommendation
Clinical Query
Stage IV NSCLC with EGFR exon 19 deletion, no prior systemic therapy. Brain metastases present. What is the recommended first-line treatment?
For Stage IV NSCLC with EGFR exon 19 deletion and brain metastases, the preferred first-line treatment is Osimertinib 80 mg PO daily (NCCN Category 1, FLAURA trial). Osimertinib demonstrates superior CNS penetration and efficacy for brain metastases compared to earlier-generation EGFR TKIs...
Supporting Evidence
Built by oncologists, for oncologists
Raphael Brandão, MD
Medical Oncologist · Clinical Computational Oncology
Chief of Oncology, São Camilo Hospital Network, São Paulo
Dana-Farber Cancer Institute / Harvard Medical School
Physician-scientist building AI tools for oncologists. OncoIA integrates clinical guidelines with machine learning to support treatment decisions at the bedside — built from 15 years of clinical practice, 80+ peer-reviewed publications, and research in immuno-oncology and early cancer detection.
23+ Tumor Types Covered
Comprehensive clinical scenarios across all major malignancies
Ready to Transform Your Clinical Workflow?
Get evidence-based oncology treatment recommendations in seconds. No login required.
No account needed